drugset / Trial / NCT03462043

A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension

NCT03462043

Phase 3 Withdrawn NeuroDerm Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This study will assess the relative bioavailability of s.c. infused ND0612 versus jejunally infused CLES in patients with advanced PD.

Timeline

Start
2018-04-10
Primary completion
2018-11-20
Completion
2018-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown Other
Subject Levodopa Small molecule Other
Subject ND0612 Unknown Subcutaneous

Indications